Vaccine delivery has long been a hot topic and only got hotter in the ongoing push to vaccinate against COVID-19 around the world. Most would probably associate vaccines with the standard “jab” injection with a syringe. Over the past year and more, companies have touted ideas for other avenues. Inovio has a “smart” delivery device […]
Auto-injectors
Baxter working on software upgrade for serious Spectrum IQ problems
Baxter (NYSE:BAX) this week issued an urgent medical device correction for all of its Spectrum IQ infusion pumps. Earlier this month, FDA designated a recall of Baxter’s Dose IQ safety software program as Class I, its most serious level. Baxter designed the Dose IQ as a standalone computer-based software program that allows care providers to […]
7 recommendations to increase training consistency for patients self-injecting biologics
Biologic drugs are finding growing success in addressing chronic diseases — from diabetes and rheumatoid arthritis to multiple sclerosis and Crohn’s. A significant rise in self-injection therapies is contributing to the trend. And yet, a recent study1 of injection naïve patients found that only 50% reported receiving a visual representation of the self-injection from a […]
Stevanato Group brings in upsized IPO worth $453.5M
Stevanato Group announced today that the underwriters of its recently completed initial public offering purchased more than 1 million additional shares. The option exercised by the underwriters saw the acquisition of an additional 1,018,280 ordinary Stevanato Group shares at $21 per share. Piombino Dese, Italy–based Stevanato Group’s IPO resulted in net proceeds of approximately $453.5 […]
FDA approves, expands label for Eli Lilly’s rapid-acting insulin for infusion
Eli Lilly (NYSE:LLY) announced today that it received FDA approval and expanded labeling for its Lyumjev rapid-acting insulin. Indianapolis-based Eli Lilly’s Lyumjev (insulin lispro-aabc injection) 100 units/mL holds indication to improve glycemic control in adults with type 1 and type 2 diabetes, including administration via continuous subcutaneous insulin infusion (CSII) with an insulin pump. The […]
Bexson Biomedical aims to extend its wearable drug delivery device to psychoactive drugs
Bexson Biomedical announced today that it launched an R&D initiative to develop subcutaneous formulations of psychoactive therapeutics. Santa Barbara, Calif.-based Bexson’s effort will apply its existing subcutaneous formulation technology to build several psychoactive drug scaffolds for treating mental health indications, including post-traumatic stress disorder (PTSD) and depression. Formulations developed through the R&D initiative are designed […]
Senseonics slides on earnings miss in Q2
Senseonics (NYSE:SENS) shares took a hit today on second-quarter results that missed the consensus earnings forecast. The Germantown, Md.-based diabetes management technology developer posted losses of –$180.3 million on sales of $3.3 million for the three months ended June 30, 2021, seeing its bottom line plummet from losses of just –$7.5 million this time last […]
Tandem Diabetes Care rises after hours on Street-beating Q2
Tandem Diabetes Care (NSDQ:TNDM) shares ticked up after hours today on second-quarter results that came in well ahead of the consensus forecast. The San Diego-based company posted profits of $4 million on sales of $172.1 million for the three months ended June 30, 2021, for a massive bottom-line gain from losses of -$27.1 million this […]
Abbott CMO Dr. Nick West touts latest iteration of drug-eluting stent
Abbott executive Dr. Nick West believes the company offers the “best-in-class” drug-eluting stent with its Xience platform. When Abbott (NYSE:ABT) CMO & divisional VP of global medical affairs for its vascular business Dr. Nick West looks back at his use of drug-eluting stents in the early 2000s, all he sees now is innovation. As a practicing interventional cardiologist, West […]
Tenaya Therapeutics prices $180M IPO for targeted therapies
Tenaya Therapeutics announced that it priced an underwritten, upsized initial public offering of common stock worth $180 million. South San Francisco-based Tenaya develops therapies for rare generic disorders and more prevalent heart conditions through gene therapy, cellular regeneration and precision medicine. The company is actively exploring different routs of administration and different infusion- and injection-based methods […]